Mendonça Regina, Gueiros Luiz Alcino, Capellaro Kátia, Pinheiro Vitória Régia Pereira, Lopes Márcio Ajudarte
Department of Oral Diagnosis, Piracicaba Dental School, Campinas State University (UNICAMP), Sao Paulo, Brazil.
Indian J Dent Res. 2011 Nov-Dec;22(6):869-70. doi: 10.4103/0970-9290.94690.
Hydroxyurea (HU) is an antimetabolic agent commonly used in myeloproliferative disorders and hematological diseases as well as in severe psoriasis. Despite of usually be well tolerated, sometimes it can induce immunosuppression and mucocutaneous adverse effects associated with discomfort or pain. Nevertheless, oral mucosal adverse reactions are extremely uncommon and present as ulcers, tongue depapilation and dyschromia. Complete remission of adverse effects is usually observed after withdrawal of the medication. The aim of this paper is to report two patients with oral lesions related to HU treatment. T0 he patients were adequately managed by changing hydroxyurea with imatinib mesilate. Oral lesions are rare complications of long-term hydroxyurea treatment and may be an indication of stopping therapy and substitution with imatinib mesilate.
羟基脲（HU）是一种抗代谢药物，常用于骨髓增殖性疾病、血液系统疾病以及重度银屑病。尽管通常耐受性良好，但有时它会诱发免疫抑制以及与不适或疼痛相关的皮肤黏膜不良反应。然而，口腔黏膜不良反应极为罕见，表现为溃疡、舌乳头萎缩和色素沉着异常。停药后通常可观察到不良反应完全缓解。本文旨在报告两例与HU治疗相关的口腔病变患者。通过将羟基脲换用甲磺酸伊马替尼，这两名患者得到了妥善处理。口腔病变是长期羟基脲治疗的罕见并发症，可能提示需要停药并换用甲磺酸伊马替尼。
